Edwards Lifesciences (EW) Shares Fresh Valve Data, Is The Stock Too Pricey?

Edwards Lifesciences (EW) has put fresh clinical data in front of cardiologists at the New York Valves 2026 conference, spotlighting its SAPIEN valve and PASCAL repair systems across multiple structural heart disease indications.

See our latest analysis for Edwards Lifesciences.

At a share price of $94.82, Edwards Lifesciences has seen a 16.04% 90 day share price return and a 24.13% 1 year total shareholder return. This suggests momentum has picked up alongside recent clinical data and index reshuffling.

If the recent clinical updates caught your attention, this can be a good moment to broaden your watchlist with other healthcare opportunities via the 40 healthcare AI stocks

For Edwards Lifesciences, a 24.13% 1 year total shareholder return, along with fresh trial data and index reshuffling, raises a simple question: is the recent move anchored in business fundamentals or driven more by changing sentiment around the stock’s profile?

Most Popular Narrative: 2.2% Undervalued

Edwards Lifesciences is trading at $94.82 against a most followed fair value narrative of about $96.92, so the stock sits only modestly below that framework.

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Read the complete narrative.

Curious what sits behind that fair value for Edwards Lifesciences? The narrative leans on a blend of faster earnings, steadier margins, and a richer future earnings multiple.

Result: Fair Value of $96.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Edwards Lifesciences still need to weigh tariff headwinds and potential EPS dilution from the JenaValve acquisition, which could pressure margins and sentiment.

Find out about the key risks to this Edwards Lifesciences narrative.

Another View on Edwards Lifesciences Valuation

While the most followed fair value narrative for Edwards Lifesciences points to the stock trading roughly 2.2% below fair value, the current P/E of 50.8x tells a tougher story. That compares with about 26.6x for the US Medical Equipment industry and a fair ratio estimate of 31.7x, which suggests investors are paying a sizable premium that could matter if sentiment cools.

To see how that premium ties back to earnings expectations and pricing power, take a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of enthusiasm and caution around Edwards Lifesciences resonates with you, consider acting promptly, review the data carefully, and weigh up the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Edwards Lifesciences?

Do not stop with Edwards Lifesciences. Broaden your opportunity set now by scanning other stocks that fit clear, disciplined criteria instead of waiting on headlines.

• Spot potential mispricings early by reviewing companies highlighted in the 45 high quality undervalued stocks before other investors start paying attention.
• Strengthen the defensive side of your portfolio by assessing companies featured in the 74 resilient stocks with low risk scores that score well on stability and resilience.
• Hunt for tomorrow's potential standouts by working through the screener containing 18 high quality undiscovered gems and focusing on quality that is not yet widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com